Cat. No. 1570
Alternative Name: CBD
Chemical Name: 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol
Biological ActivityNon-psychotropic constituent of cannabis that is anticonvulsive, antihyperalgesic and neuroprotective in vivo. GPR55 and weak CB1 antagonist (IC50 values are 0.445 and 3.35 μM), CB2 receptor inverse agonist and inhibitor of anandamide uptake (IC50 = 27.5 μM). Also a weak agonist at VR1 vanilloid receptors (EC50 = 3.5 μM).
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Petitet et al (1998) Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of Δ9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci. 63 PL1. PMID: 9667767.
Costa et al (2004) Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br.J.Pharmacol. 143 247. PMID: 15313881.
Ryberg et al (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br.J.Pharmacol. 152 1092. PMID: 17876302.
Thomas et al (2007) Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br.J.Pharmacol. 150 613. PMID: 17245363.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: (-)-Cannabidiol, supplier, Natural, cannabinoids, AMT, inhibitors, GPR55, antagonists, weak, CB1, CB2, inverse, agonists, Anandamide, Transporters, Monoamine, Neurotransmitter, Non-Selective, Receptors, cb2r, cb1r
Find multiple products by catalog number
New Products in this Area
Selective GPR55 antagonist
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.